Bone Metastasis in Solid Tumors Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn

Posted on
by

Bone Metastasis in Solid Tumors Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn
DelveInsight’s “Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bone Metastasis in Solid Tumors, historical and forecasted epidemiology as well as the Bone Metastasis in Solid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bone Metastasis in Solid Tumors, historical and forecasted epidemiology as well as the Bone Metastasis in Solid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Bone Metastasis in Solid Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bone Metastasis in Solid Tumors Market Forecast

 

Some of the key facts of the Bone Metastasis in Solid Tumors Market Report: 

  • The Bone Metastasis in Solid Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The rate of bone metastases is 23.19% in SCLC, 22.50% in NSCLC (NOS/others), 20.28% in ADC, 8.44% in squamous cell carcinoma of the lung (SCC), and 4.11% in bronchioloalveolar carcinoma [NSCLC (BAC)] according to the study by Huang et al. (2020)
  • Metastatic bone disease is frequently seen in specific cancer types, particularly in metastasis arising from the breast (70%), prostate (85%), lung (40%), and kidney (40%) cancer types, according to a study by Coleman et al. (2020)
  • Approximately 400,000 new cases of malignant bone metastasis are identified in the US each year, according to the American Cancer Society (ACS). Additionally, according to the ACS, people with advanced prostate cancer and breast cancer are more likely than other patients to have malignant tumours with bone metastases (30–75%)
  • According to a study by Ryan et al. (2022), 5.1% of cancer patients in the SEER database had bone metastasis diagnoses, which equates to about 18.8 per 100,000 diagnoses in the US every year from 2010 to 2015. In this study, men made up 57.8% of the patients with solid tumours that had bone metastases
  • The development of NanaBis is currently moving forward in Phase III at Medlab, and if the tests are successful, an FDA NDA application might be submitted by the end of 2024
  • Key Bone Metastasis in Solid Tumors Companies: NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others
  • Key Bone Metastasis in Solid Tumors Therapies: Medlab Clinical, Elraglusib, MW032, Ibandronate, Zoledronic acid, Fragmin, Fentanyl sublingual spray, and others
  • The Bone Metastasis in Solid Tumors epidemiology based on gender analyzed that men are more likely to develop bone metastasis in solid tumors than females
  • The Bone Metastasis in Solid Tumors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bone Metastasis in Solid Tumors pipeline products will significantly revolutionize the Bone Metastasis in Solid Tumors market dynamics.

 

Bone Metastasis in Solid Tumors Overview

When cancer cells migrate from their primary site to a bone, this is known as bone metastasis. Almost all cancers have the ability to “metastasize” (spread) to the bones. However, some cancers, such as breast and prostate cancer, are more prone than others to spread to the bone.

 

Get a Free sample for the Bone Metastasis in Solid Tumors Market Report 

https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market

 

Bone Metastasis in Solid Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Bone Metastasis in Solid Tumors Epidemiology Segmentation:

The Bone Metastasis in Solid Tumors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Bone Metastasis in Solid Tumors
  • Prevalent Cases of Bone Metastasis in Solid Tumors by severity
  • Gender-specific Prevalence of Bone Metastasis in Solid Tumors
  • Diagnosed Cases of Episodic and Chronic Bone Metastasis in Solid Tumors

 

Download the report to understand which factors are driving Bone Metastasis in Solid Tumors epidemiology trends @ Bone Metastasis in Solid Tumors Epidemiology Forecast

 

Bone Metastasis in Solid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bone Metastasis in Solid Tumors market or expected to get launched during the study period. The analysis covers Bone Metastasis in Solid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bone Metastasis in Solid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Bone Metastasis in Solid Tumors Therapies and Key Companies

  • Medlab Clinical: NanaBis
  • Elraglusib: Actuate Therapeutics
  • MW032: Mabwell Bioscience
  • Ibandronate: Hoffmann-La Roche
  • Zoledronic acid: Novartis
  • Fragmin: Upjohn
  • Fentanyl sublingual spray: INSYS Therapeutics Inc

 

Discover more about therapies set to grab major Bone Metastasis in Solid Tumors market share @ Bone Metastasis in Solid Tumors Treatment Market

 

Scope of the Bone Metastasis in Solid Tumors Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Bone Metastasis in Solid Tumors Companies: NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others
  • Key Bone Metastasis in Solid Tumors Therapies: Medlab Clinical, Elraglusib, MW032, Ibandronate, Zoledronic acid, Fragmin, Fentanyl sublingual spray, and others
  • Bone Metastasis in Solid Tumors Therapeutic Assessment: Bone Metastasis in Solid Tumors current marketed and Bone Metastasis in Solid Tumors emerging therapies
  • Bone Metastasis in Solid Tumors Market Dynamics: Bone Metastasis in Solid Tumors market drivers and Bone Metastasis in Solid Tumors market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Bone Metastasis in Solid Tumors Unmet Needs, KOL’s views, Analyst’s views, Bone Metastasis in Solid Tumors Market Access and Reimbursement 

 

To know more about Bone Metastasis in Solid Tumors companies working in the treatment market, visit @ Bone Metastasis in Solid Tumors Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Bone Metastasis in Solid Tumors Market Report Introduction

2. Executive Summary for Bone Metastasis in Solid Tumors

3. SWOT analysis of Bone Metastasis in Solid Tumors

4. Bone Metastasis in Solid Tumors Patient Share (%) Overview at a Glance

5. Bone Metastasis in Solid Tumors Market Overview at a Glance

6. Bone Metastasis in Solid Tumors Disease Background and Overview

7. Bone Metastasis in Solid Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Bone Metastasis in Solid Tumors 

9. Bone Metastasis in Solid Tumors Current Treatment and Medical Practices

10. Bone Metastasis in Solid Tumors Unmet Needs

11. Bone Metastasis in Solid Tumors Emerging Therapies

12. Bone Metastasis in Solid Tumors Market Outlook

13. Country-Wise Bone Metastasis in Solid Tumors Market Analysis (2019–2032)

14. Bone Metastasis in Solid Tumors Market Access and Reimbursement of Therapies

15. Bone Metastasis in Solid Tumors Market Drivers

16. Bone Metastasis in Solid Tumors Market Barriers

17.  Bone Metastasis in Solid Tumors Appendix

18. Bone Metastasis in Solid Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services